

CLAIMS

1. An aqueous liquid preparation comprising 2-amino-3-(4-bromobenzoyl)phenylacetic acid or a pharmacologically acceptable salt thereof or a hydrate thereof, and an alkyl aryl polyether alcohol type polymer or a polyethylene glycol fatty acid ester.

2. The aqueous liquid preparation according to claim 1, wherein the

alkyl aryl polyether alcohol type polymer has a polymerization degree of 3 to 10, the alkyl contains 1 to 18 carbon atoms, the aryl is a phenyl residue, and the polyether alcohol is represented by the formula $O(CH_2CH_2O)_xH$ in which X is an integer of 5 to 100.

3. The aqueous liquid preparation according to claim 1 or 2, wherein the alkyl aryl polyether alcohol type polymer is tyloxapol.

4. The aqueous liquid preparation according to claim 1, wherein the carbon number of the fatty acid in the polyethylene glycol fatty acid ester is 12 to 18.

5. The aqueous liquid preparation according to claim 1 or 4, wherein the polyethylene glycol fatty acid ester is polyethylene glycol monostearate.

6. The aqueous liquid preparation according to any one of claims 1 to 3, wherein the concentration of the alkyl aryl polyether alcohol type polymer is selected from a range of minimum concentration of 0.01 w/v % to maximum concentration of 0.5 w/v %.

7. The aqueous liquid preparation according to any one of claims 1, 2 or 4, wherein the concentration of the polyethylene glycol fatty acid ester is selected from a range of minimum concentration of 0.02 w/v % to maximum concentration of 0.1 w/v %.

8. The aqueous liquid preparation according to any one of claims 1 to 7, wherein the concentration of the 2-amino-3-(4-bromobenzoyl)phenylacetic acid or a pharmacologically acceptable salt thereof or a hydrate thereof is 0.01 to 0.5 w/v %.

9. The aqueous liquid preparation according to any one of claims 1 to 8, wherein benzalkonium chloride is contained as a preservative.

10. The aqueous liquid preparation according to any one of 1 to 9, wherein the pharmacologically acceptable salt of 2-amino-3-(4-bromobenzoyl)phenylacetic acid is a sodium salt.

11. The aqueous liquid preparation according to any one of claims 1 to 10, wherein the pH of the aqueous liquid preparation is within a range of 7 to 9.

12. The aqueous liquid preparation according to claim 11, wherein the pH of the aqueous liquid preparation is within a range of 7.5 to 8.5.

5

13. The aqueous liquid preparation according to any one of claims 1 to 12, wherein the aqueous liquid preparation is an eye drop.

10

14. The aqueous liquid preparation according to any one of claims 1 to 12, wherein the aqueous liquid preparation is a nasal drop.

15

15. An eye drop comprising sodium 2-amino-3-(4-bromobenzoyl)phenylacetate hydrate and 0.01 to 0.5 w/v % of tyloxapol.

20

16. An eye drop comprising sodium 2-amino-3-(4-bromobenzoyl)phenylacetate hydrate and 0.02 to 0.1 w/v % of polyethylene glycol monostearate.

25

17. A method for stabilizing 2-amino-3-(4-bromobenzoyl)phenylacetic acid or a pharmacologically acceptable salt thereof or a hydrate thereof in an aqueous liquid preparation, which comprises incorporating tyloxapol or polyethylene glycol monostearate into an aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid or a pharmacologically acceptable salt thereof or a hydrate

thereof.

18. A method for inhibiting decrease in preservative effect
of a preservative in an aqueous liquid preparation of
5 2-amino-3-(4- bromobenzoyl)phenylacetic acid or a
pharmacologically acceptable salt thereof or a hydrate thereof,
which comprises incorporating tyloxapol or polyethylene glycol
monostearate into an aqueous liquid preparation containing
2-amino-3-(4- bromobenzoyl)phenylacetic acid or a
10 pharmacologically acceptable salt thereof or a hydrate thereof
and a preservative.